The researches find that the Tumor Center at the Barrow Neurological Institute, has released the results of its recent Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali) for the treatment of recurrent glioblastoma. Therefore The agent, recently approved by the FDA for advanced breast cancer, is part of a newly-discovered class of targeted therapy that undermines cancer cell division and could form the backbone of a new drug cocktail for patients with malignant brain tumors like glioblastoma.

Class of targeted therapy

Glioblastoma presents singular, complex challenges as compared to other types of cancer. You are not dealing with a single entity; but rather a collection of genetic variants that differ from patient to patient. This Phase 0 clinical trial used a precision medicine approach to uncover which subtypes of glioblastoma may respond to ribociclib and how our patients’ tumors developed resistance to the new therapy.”

Dr. Nader Sanai, director of the Ivy Brain Tumor Center Results from the trial show that ribociclib is uniquely capable of breaking through the blood-brain barrier; a critical obstacle that for years has stalled drug development in brain tumor patients; and that the drug effectively hits its molecular target in cancer cells.  The experimental Phase 0 clinical trial design also identifies a potential mechanism of drug resistance; which the Ivy Brain Tumor Center clinical trials team is now exploiting as part of an ongoing drug cocktail trial for recurrent glioblastoma patients.

The drug effectively

“This comprehensive study has helped us to identify a potent combined-drug regimen to undermine a glioblastoma resistance mechanism to ribociclib. In less than a year; we have make tremendous progress in moving towards creating a new drug cocktail, which is significant given how precious time is for both patients and physicians fighting this disease;” said Dr. Sanai. his section explains the types of treatments that are the standard of care for early-stage and locally advanced breast cancer.

“Standard of care” means the best treatments known. When making treatment plan decisions; you are encourage to consider clinical trials as an option. A clinical trial is a research study that tests a new approach to treatment. Doctors want to learn whether the new treatment is safe; effective, and possibly better than the standard treatment. Clinical trials can test a new drug and how often it should be given; a new combination of standard treatments, or new doses of standard drugs or other treatments. Some clinical trials also test giving less treatment than what is usually done as standard of care.